Abbott acquires Sanofi's Carpuject system:
This article was originally published in Clinica
Executive Summary
Abbott Laboratories is paying $200 million to Sanofi Pharmaceuticals for certain parenteral products businesses. Abbott gains the rights to pre-filled, single-dose syringe technology with Sanofi's Carpuject drug delivery system. In addition, Abbott obtains a range of multi-source injectable drugs. Abbott said these products complement its existing line of FirstChoice generic injectables and its drug delivery systems.